AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Reasons for Changing HOrmonal Therapy of Advanced Breast Cancer
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2010-12-23
- Last Posted Date
- 2011-11-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 234
- Registration Number
- NCT01265654
- Locations
- 🇨🇿
Research Site, Znojmo, Czech Republic
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Phase 2
Terminated
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Placebo of fostamatinib, fostamatinib, and placebo injections
- First Posted Date
- 2010-12-22
- Last Posted Date
- 2014-05-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 644
- Registration Number
- NCT01264770
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
Prevalence of Subclinical Atherosclerosis and Its Associated Factors in Hyperlipidemic Korean Adults With Diabetes
Completed
- Conditions
- Diabetes MellitusDyslipidemia
- First Posted Date
- 2010-12-21
- Last Posted Date
- 2012-03-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 181
- Registration Number
- NCT01264263
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
A Study to Assess the Safety, Tolerability and Pharmacokinetics After Single Ascending Intravenous Doses of AZD2927 in Healthy Male Volunteers
- First Posted Date
- 2010-12-21
- Last Posted Date
- 2011-05-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT01264250
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects
- First Posted Date
- 2010-12-10
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT01258205
- Locations
- 🇺🇸
Stony Brook University Medical Center, Stony Brook, New York, United States
🇦🇺QPharm Pty Limited, Herston, Queensland, Australia
🇦🇺Clinical Medical and Analytical eXellence CMAX, Adelaide, South Australia, Australia
Non-interventional Study (NIS) to Assess Reaching of Cholesterol Target Values in Patients Treated With HMG-CoA Reductase Inhibitors
Completed
- Conditions
- Hypercholesterolaemia
- First Posted Date
- 2010-12-10
- Last Posted Date
- 2012-03-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1868
- Registration Number
- NCT01257971
- Locations
- 🇭🇷
Research Site, Zagreb, Croatia
Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis Turbuhaler
Early Phase 1
Completed
- Conditions
- COPD Method EvaluationChronic Obstructive Pulmonary Disease Method Evaluation
- Interventions
- Drug: Budesonide/Formoterol Turbuhaler
- First Posted Date
- 2010-12-09
- Last Posted Date
- 2012-09-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 34
- Registration Number
- NCT01257048
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone
- First Posted Date
- 2010-12-09
- Last Posted Date
- 2012-03-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 375
- Registration Number
- NCT01257412
- Locations
- 🇮🇳
Research Site, Ghaziabad, Uttar Pradesh, India
Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression
Phase 3
Completed
- Conditions
- Bipolar Depression
- Interventions
- First Posted Date
- 2010-12-08
- Last Posted Date
- 2016-04-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 361
- Registration Number
- NCT01256177
- Locations
- 🇨🇳
Research Site, Xian, China
Functional Assessment of Patients With Acute Bipolar Depression After 8 Months of Follow-up
Completed
- Conditions
- Bipolar DisorderBipolar Depression
- First Posted Date
- 2010-12-08
- Last Posted Date
- 2012-10-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 249
- Registration Number
- NCT01255982
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain